Treatment with low-dose doxorubicin or cisplatin elevates REDD1 expression and reduces mTORC1-dependent translation of VEGF receptor-2/3 and eNOS in TECs and endothelial progenitor cells, all of these effects are inhibited in Redd1-deficient cells, resulting in suppressed tumor angiogenesis and lymphangiogenesis, thereby inhibiting tumor growth and metastasis18,158. Here, DDIT4 is linked to neoplasm.